Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome.

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Ketamine and Esketamine intravenous perfusions can modulate chronic pain. The purpose of this study is to determine if Ketamine or Esketamine are favorable for outpatients suffering from fibromyalgia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Charleroi
• Collaborator: Centre Hospitalier Universitaire de Liège
• Treatments: Esketamine; Ketamine

Criteria

Inclusion Criteria:

• Male and female

• Between 18 and 75 years old

• Reads and writes French

• Diagnosis of fibromyalgia syndrome according to Widespread Pain Index (WPI) and Symptom Severity Scale (SSS) score ≥ 13/31

• Both molecules (Ketamine and Esketamine) were administered at least once during an analgesic infusion session in Pain Clinic

• Patient with regular medical follow-up by a pain specialist at least 3 times a year

Exclusion Criteria:

• Allergy or intolerance to Ketamine or Esketamine

• Current infection, fever

• Pregnant or breastfeeding woman

• Serious cardiovascular disorders and severe hypertension

• Increased pressure of cerebrospinal fluid and severe intracranial disease

• Acute intermittent porphyria

• Untreated epilepsy

• Untreated glaucoma

• Difficult or impossible intravenous access

• Chronic Liver Disease Child-Pugh C